Cartesian Therapeutics, Inc. · NASDAQ:RNAC
Cartesian Therapeutics — Merger or Acquisition (November 2023)
24 slides from Cartesian Therapeutics's merger presentation, Nov 13, 2023
Slide 1: Merger Announcement
Merger Announcement November 13, 2023
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Selecta Biosciences, Inc. (“Selecta”) and Cartesian Therapeutics, Inc
Slide 3: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements No Offer or Solicitation; Important Information About the Merger and Where to Find It This presentation is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Merger and shall not co
Slide 4: Selecta and Cartesian merger creates publicly traded company pioneering RNA cell therapy
Selecta and Cartesian merger creates publicly traded company pioneering RNA cell therapy to treat autoimmune disease • Leader in RNA cell therapy for the treatment of autoimmune diseases Cartesian Opportunity • Deep pipeline of autoimmune programs • Strong IP portfolio Clinically Validated Lead • De
Slide 5: Summary of Transaction
Summary of Transaction Stock-for-stock transaction • All of Cartesian’s outstanding equity interests were exchanged for a combination of shares of Selecta common stock and a newly created non-voting Series A convertible preferred stock • Surviving entity name / ticker: Cartesian Therapeutics / “RNAC
Slide 6: Combined organization overview
Combined organization overview Management Select Board Members Carsten Brunn, PhD Blaine Davis Metin Kurtoglu, MD, PhD Emily English, PhD Carrie S. Cox Timothy Springer, PhD President and CEO CFO COO VP, Quality Chairman Director Chris Jewell, PhD Milos Miljkovic, MD Matthew Bartholomae Murat Kalayo
Slide 7: Cartesian – Clinical-stage company pioneering RNA cell therapy for autoimmunity
Cartesian – Clinical-stage company pioneering RNA cell therapy for autoimmunity Expanding the Reach In-House Promising Robust Pipeline Based and Potential of Cell Manufacturing and Lead Asset on Proprietary Platform Therapy R&D • RNA cell therapies do not • Descartes-08, a potential • Wholly-owned,
Slide 8: In-house manufacturing enhances control of product quality, production schedules and costs
In-house manufacturing enhances control of product quality, production schedules and costs cGMP Cell Manufacturing State-of-the-art facility with dedicated QMS cGMP RNA Quality Control Synthesis Internal assay validation and lot release Large-scale RNA production Process MSC Cell Banking Development
Slide 9: Conventional engineered cell therapy uses DNA, which can lead to toxicity and high cost
Conventional engineered cell therapy uses DNA, which can lead to toxicity and high cost DNA transduced CAR-T associated with: • Effector function of cell therapy engineered with DNA amplifies • Cytokine release syndrome (CRS) exponentially with cell replication, frequently leading to uncontrollable
Slide 10: Cartesian's RNA approach designed to expand reach of cell therapy to autoimmunity
Cartesian’s RNA approach designed to expand reach of cell therapy to autoimmunity with safer, potent, and less expensive therapies Descartes-08 has been administered to 66 • mRNA does not replicate → predictable half-life with more controllable patients with autoimmune diseases and PK/PD defined by
Slide 11: Wholly-owned pipeline targets autoimmune disease
Wholly-owned pipeline targets autoimmune disease Discovery/ Asset Indications Phase 1 Phase 2 Pivotal Preclinical Myasthenia Gravis Data from Phase 2b study expected in mid-2024 Descartes-08 Autologous rCAR-T Expect to initiate Phase 2 studies in SLE, ocular and vasculitic SLE, other AAAD autoimmune
Slide 12: Initial indication for Descartes-08: Myasthenia gravis
Initial indication for Descartes-08: Myasthenia gravis • Affects over 120,000 patients in US and EU • Characterized by debilitating weakness: limbs, respiratory, ocular, facial muscles • Standard of care includes chronic use of immunosuppressants, which are often toxic • Progressive disease that is
Slide 13: Descartes-08 is believed to be the first rCAR-T in clinical development for autoimmune disease
Descartes-08 is believed to be the first rCAR-T in clinical development for autoimmune disease • Engineered by transfection of autologous CD8+ T cells with mRNA encoding anti-BCMA CAR • Typical lot processed for infusion within ~3 weeks • Observed to enhance killing and suppression of inflammatory c
Slide 14: Phase 2 study of Descartes-08 in MG (NCT04146051)
Phase 2 study of Descartes-08 in MG (NCT04146051) Patient eligibility Part 1: Identify safe dose All doses safe and • MG-ADL > 6 well-tolerated • MGFA Class II-IV (n = 3) • Stable medication dosing > 8 wks prior to infusion Complete • 4-week washout for biologics • IVIg and plasma exchange not allow
Slide 15: Phase 2a study population comprises patients with significant disease
Phase 2a study population comprises patients with significant disease • Baseline MG-ADL mean score of 10 • 79% were MGFA Class III-IV at screening • All patients presented with disease that was not well- managed under standard of care therapies 15
Slide 16: Descartes-08 was observed to be safe and well-tolerated in MG
Descartes-08 was observed to be safe and well-tolerated in MG Key observations: • No dose-limiting toxicities • No cytokine release syndrome • No neurotoxicity • No pre-treatment chemo, so no induced hematological toxicities • Outpatient treatment 16
Slide 17: Descartes-08 observed to induce deep and durable clinical improvement in MG
Descartes-08 observed to induce deep and durable clinical improvement in MG Treatment finished Treatment finished • Unprecedented magnitude and duration of response across all 4 standard MG severity scales Treatment finished Treatment finished • Responses appear to deepen after completing treatment
Slide 18: Phase 2b randomized, placebo-controlled, double-masked study of Descartes-08 in MG
Phase 2b randomized, placebo-controlled, double-masked study of Descartes-08 in MG Plan to treat ~30 patients Primary endpoint • Proportion of MG ADL responders (≥6-point reduction) at Day 85 Secondary objectives • Safety and tolerability • Quantify clinical effect of Descartes-08 over 1 year • QMG,
Slide 19: Exploring additional applications for Descartes-08 in autoantibody-associated autoimmune diseases
Exploring additional applications for Descartes-08 in autoantibody-associated autoimmune diseases Potential significant Descartes-08-associated improvement observed in a patient with autoimmune retinitis (AIR) 61-year-old man with DPPX antibody-positive AIR, colitis, encephalitis refractory to predn
Slide 20: RNA Armory example: Descartes-15, a next generation anti-BCMA rCAR-T
RNA Armory® example: Descartes-15, a next generation anti-BCMA rCAR-T with >10x potency Descartes-15 is an anti-BCMA CAR with Potent killing (single target exposure) Persistent killing (multiple exposures) disruptive features: 100 Descartes-15 DC-15 100 Descartes-15 DC-15 Descartes-08 Descartes-08 D
Slide 21: Platform offers potential development opportunities via three modalities
Platform offers potential development opportunities via three modalities: autologous, allogeneic and in situ rCAR-T: Autologous RNA cell therapy • Descartes-08 • Descartes-15: next generation anti- BCMA rCAR-T with >10x potency rMSC: Allogeneic RNA cell therapy • Descartes-33 rLN: In vivo lymph node
Slide 22: Maturing pipeline offers potential for multiple value creating events
Maturing pipeline offers potential for multiple value creating events Descartes-08 in MG • Expect to report Phase 2b data mid-2024 Funding to support development of Descartes-08 in SLE Descartes-08 through Phase 3 and advance • Plan to initiate Phase 2 in 1H 2024 additional programs Anticipate >$110
Slide 23: Selecta and Cartesian merger to create publicly traded company pioneering RNA cell therapy
Selecta and Cartesian merger to create publicly traded company pioneering RNA cell therapy to treat autoimmune disease • Leader in RNA cell therapy with approach to treating autoimmune disease Cartesian Opportunity • Deep pipeline of autoimmune programs Clinically Validated Lead • Descartes-08: obse
Slide 24: Merger Announcement
Merger Announcement November 13, 2023
Cartesian Therapeutics — Merger or Acquisition (November 2023) on 6ix